miR-663 induces castration-resistant prostate cancer transformation and predicts clinical recurrence.
Castration-resistant prostate cancer (CRPC) and its treatment are challenging issues in prostate cancer management. Here, we report that miR-663 is upregulated in CRPC tissues. Overexpression of miR-663 in prostate LNCaP cells promotes cell proliferation and invasion, neuroendocrine differentiation, and reduction in dihydrotestosterone-induced upregulation of prostate-specific antigen expression. Furthermore, results of in situ hybridization show that miR-663 expression is correlated with Gleason score and TNM stage and is an independent prognostic predictor of clinical recurrence. Together, these findings suggest that miR-663 is a potential oncomiR for CRPC and may serve as a tumor biomarker for the early diagnosis of CRPC.
Department of Urology, Second Military Medical University, Changhai Hospital, Shanghai, China.
Li
L
Jiao
Zhen
Z
Deng
Chuanliang
C
Xu
Yongwei
Y
Yu
Yun
Y
Li
Chun
C
Yang
Junyi
J
Chen
Zhiyong
Z
Liu
Gang
G
Huang
Long-Cheng
LC
Li
Yinghao
Y
Sun
D014408:Biomarkers, Tumor / Q000235:genetics; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D055088:Early Detection of Cancer; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000096:biosynthesis / Q000235:genetics*; D009361:Neoplasm Invasiveness / Q000235:genetics; D009364:Neoplasm Recurrence, Local / Q000235:genetics* / Q000473:pathology; D064129:Prostatic Neoplasms, Castration-Resistant / Q000175:diagnosis* / Q000235:genetics* / Q000473:pathology
D014408:Biomarkers, Tumor; C552243:MIRN663 microRNA, human; D035683:MicroRNAs